Prospective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma
Antonio M Fea,1 Jose I Belda,2 Marek Rękas,3 Anselm Jünemann,4 Lydia Chang,5 Luis Pablo,6 Lilit Voskanyan,7 L Jay Katz81Università degli Studi di Torino, Clinica Oculistica, Torino, Italy; 2Hospital Torrevieja Salud, UTE, Servicio de Oftalmologia, Alicante, Spain; 3Military Inst...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/37ee594eb7824d61b0ad0fc53a693824 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:37ee594eb7824d61b0ad0fc53a693824 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:37ee594eb7824d61b0ad0fc53a6938242021-12-02T07:23:19ZProspective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma1177-5483https://doaj.org/article/37ee594eb7824d61b0ad0fc53a6938242014-05-01T00:00:00Zhttp://www.dovepress.com/prospective-unmasked-randomized-evaluation-of-the-istent-injectreg-ver-a16704https://doaj.org/toc/1177-5483 Antonio M Fea,1 Jose I Belda,2 Marek Rękas,3 Anselm Jünemann,4 Lydia Chang,5 Luis Pablo,6 Lilit Voskanyan,7 L Jay Katz81Università degli Studi di Torino, Clinica Oculistica, Torino, Italy; 2Hospital Torrevieja Salud, UTE, Servicio de Oftalmologia, Alicante, Spain; 3Military Institute of Medicine, Department of Ophthalmology, Warsaw, Poland; 4Universitätsaugenklinik, Erlangen, Germany; 5Hinchingbrooke Hospital NHS Trust and Moorfields Bedford Hospital NHS Trust, United Kingdom; 6Hospital Universitario Miguel Servet, Servicio Oftalmologico, Zaragoza, Spain; 7SV Malayan Ophthalmological Center, Yerevan, Armenia; 8Wills Eye Institute, Jefferson Medical College, Philadelphia, PA, USAPurpose: The purpose of this study was to compare outcomes of subjects with open-angle glaucoma (OAG) not controlled on one medication who underwent either implantation of two iStent inject® trabecular micro-bypass devices or received medical therapy consisting of a fixed combination of latanoprost/timolol.Patients and methods: Of 192 subjects who qualified for the study and were enrolled, 94 were randomized to surgery with implantation of two iStent inject® devices in the treated eye and 98 to receive medical therapy.Results: At the month 12 visit, 94.7% of eyes (89/94) in the stent group reported an unmedicated intraocular pressure (IOP) reduction of ≥20% versus baseline unmedicated IOP, and 91.8% of eyes (88/98) in the medical therapy group reported an IOP reduction ≥20% versus baseline unmedicated IOP. A 17.5% between-group treatment difference in favor of the iStent inject group was statistically significant (P=0.02) at the ≥50% level of IOP reduction. An IOP ≤18 mmHg was reported in 92.6% of eyes (87/94) in the iStent inject group and 89.8% of eyes (88/98) in the medical therapy group. Mean (standard deviation) IOP decreases from screening of 8.1 (2.6) mmHg and 7.3 (2.2) mmHg were reported in the iStent inject and medical therapy groups, respectively. A high safety profile was also noted in this study in both the iStent inject and medical therapy groups, as measured by stable best corrected visual acuity, cup-to-disc ratio, and adverse events.Conclusion: These data show that the use of iStent inject is at least as effective as two medications, with the clinical benefit of reducing medication burden and assuring continuous treatment with full compliance to implant therapy as well as having a highly favorable safety profile.Keywords: ab interno, intraocular pressure, trabecular bypass, OAG, IOP reductionFea AMBelda JIRękas MJünemann AChang LPablo LVoskanyan LKatz LJDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 875-882 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Ophthalmology RE1-994 |
| spellingShingle |
Ophthalmology RE1-994 Fea AM Belda JI Rękas M Jünemann A Chang L Pablo L Voskanyan L Katz LJ Prospective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma |
| description |
Antonio M Fea,1 Jose I Belda,2 Marek Rękas,3 Anselm Jünemann,4 Lydia Chang,5 Luis Pablo,6 Lilit Voskanyan,7 L Jay Katz81Università degli Studi di Torino, Clinica Oculistica, Torino, Italy; 2Hospital Torrevieja Salud, UTE, Servicio de Oftalmologia, Alicante, Spain; 3Military Institute of Medicine, Department of Ophthalmology, Warsaw, Poland; 4Universitätsaugenklinik, Erlangen, Germany; 5Hinchingbrooke Hospital NHS Trust and Moorfields Bedford Hospital NHS Trust, United Kingdom; 6Hospital Universitario Miguel Servet, Servicio Oftalmologico, Zaragoza, Spain; 7SV Malayan Ophthalmological Center, Yerevan, Armenia; 8Wills Eye Institute, Jefferson Medical College, Philadelphia, PA, USAPurpose: The purpose of this study was to compare outcomes of subjects with open-angle glaucoma (OAG) not controlled on one medication who underwent either implantation of two iStent inject® trabecular micro-bypass devices or received medical therapy consisting of a fixed combination of latanoprost/timolol.Patients and methods: Of 192 subjects who qualified for the study and were enrolled, 94 were randomized to surgery with implantation of two iStent inject® devices in the treated eye and 98 to receive medical therapy.Results: At the month 12 visit, 94.7% of eyes (89/94) in the stent group reported an unmedicated intraocular pressure (IOP) reduction of ≥20% versus baseline unmedicated IOP, and 91.8% of eyes (88/98) in the medical therapy group reported an IOP reduction ≥20% versus baseline unmedicated IOP. A 17.5% between-group treatment difference in favor of the iStent inject group was statistically significant (P=0.02) at the ≥50% level of IOP reduction. An IOP ≤18 mmHg was reported in 92.6% of eyes (87/94) in the iStent inject group and 89.8% of eyes (88/98) in the medical therapy group. Mean (standard deviation) IOP decreases from screening of 8.1 (2.6) mmHg and 7.3 (2.2) mmHg were reported in the iStent inject and medical therapy groups, respectively. A high safety profile was also noted in this study in both the iStent inject and medical therapy groups, as measured by stable best corrected visual acuity, cup-to-disc ratio, and adverse events.Conclusion: These data show that the use of iStent inject is at least as effective as two medications, with the clinical benefit of reducing medication burden and assuring continuous treatment with full compliance to implant therapy as well as having a highly favorable safety profile.Keywords: ab interno, intraocular pressure, trabecular bypass, OAG, IOP reduction |
| format |
article |
| author |
Fea AM Belda JI Rękas M Jünemann A Chang L Pablo L Voskanyan L Katz LJ |
| author_facet |
Fea AM Belda JI Rękas M Jünemann A Chang L Pablo L Voskanyan L Katz LJ |
| author_sort |
Fea AM |
| title |
Prospective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma |
| title_short |
Prospective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma |
| title_full |
Prospective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma |
| title_fullStr |
Prospective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma |
| title_full_unstemmed |
Prospective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma |
| title_sort |
prospective unmasked randomized evaluation of the istent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma |
| publisher |
Dove Medical Press |
| publishDate |
2014 |
| url |
https://doaj.org/article/37ee594eb7824d61b0ad0fc53a693824 |
| work_keys_str_mv |
AT feaam prospectiveunmaskedrandomizedevaluationoftheistentinjectregversustwoocularhypotensiveagentsinpatientswithprimaryopenangleglaucoma AT beldaji prospectiveunmaskedrandomizedevaluationoftheistentinjectregversustwoocularhypotensiveagentsinpatientswithprimaryopenangleglaucoma AT rekasm prospectiveunmaskedrandomizedevaluationoftheistentinjectregversustwoocularhypotensiveagentsinpatientswithprimaryopenangleglaucoma AT juumlnemanna prospectiveunmaskedrandomizedevaluationoftheistentinjectregversustwoocularhypotensiveagentsinpatientswithprimaryopenangleglaucoma AT changl prospectiveunmaskedrandomizedevaluationoftheistentinjectregversustwoocularhypotensiveagentsinpatientswithprimaryopenangleglaucoma AT pablol prospectiveunmaskedrandomizedevaluationoftheistentinjectregversustwoocularhypotensiveagentsinpatientswithprimaryopenangleglaucoma AT voskanyanl prospectiveunmaskedrandomizedevaluationoftheistentinjectregversustwoocularhypotensiveagentsinpatientswithprimaryopenangleglaucoma AT katzlj prospectiveunmaskedrandomizedevaluationoftheistentinjectregversustwoocularhypotensiveagentsinpatientswithprimaryopenangleglaucoma |
| _version_ |
1718399450676723712 |